Archive: Company News
Company News: Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines
Prof. Ugur Sahin, Managing Director Research and Science at TRON (Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz gGmbH), has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The SUMMIT project will be conducted by Prof. Sahin and his team at TRON, an internationally leading research institute in the development of personalized therapy concepts and biomarkers in the field of oncology.
Company News: Curetis: Novel Products and Study Data to be Presented at ECCMID 2018
— Introduction of Unyvero UTI Application Cartridge
— Update on A30 RQ Analyzer to be provided
— MGI/Curetis NGS Solution for Molecular Microbiology to be featured
Curetis N.V. (the “Company” and, together with Curetis USA Inc. and Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company and its subsidiary Ares Genetics GmbH will present novel products, data, and services during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Madrid, Spain, from April 21 – 24, 2018. Curetis and Ares Genetics can be found at booth #79, hall 10, during the conference.
Company News: Curetis Establishes U.S. Scientific Advisory Board
— U.S. Scientific Advisory Board formed with five renowned infectious disease specialists
— Expands Curetis’ scientific network and clinical expertise to support U.S. adoption of recently cleared Unyvero System and LRT Cartridge
Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc., “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has established a dedicated U.S. Scientific Advisory Board.
Company News: New microDTTect solution improves diagnosis of periprosthetic infections
With the European launch of microDTTect Heraeus is now offering a novel solution for the diagnosis of periprosthetic infections. For the first time, orthopedists and microbiology labs can use a closed system allowing the contamination-free removal of bacterial biofilms on tissue and sample materials for further analysis. In the lab, microDTTect has demonstrated enhanced sensitivity and specificity in microbial detection of up to 94%, thereby significantly facilitating the correct diagnosis and treatment of biofilm-associated infections.